Neurological immune-related adverse events of ipilimumab.
Pract Neurol
; 13(4): 278-80, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23487828
ABSTRACT
Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment hypophysitis, meningitis and Guillain-Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fatores Imunológicos
/
Melanoma
/
Anticorpos Monoclonais
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pract Neurol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Holanda